证券代码：000739 证券简称：普洛药业 公告编号：2025-73 普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2025 年 11 月 5 日，普洛药业股份有限公司（以下简称"公司"）与中 国银行股份有限公司东阳支行（以下简称"中国银行"）签订《保证合同》（合 同编号：横店 2025 年人保字 176 号），同意为公司全资子公司浙江普洛家园药 业有限公司与中国银行签署的《流动资金借款合同》（合同编号：横店 2025 年 人借字 176 号）中的 2,000 万元流动资金贷款提供连带责任保证，担保期限 12 个月。 2、2025 年 11 月 6 日，公司与中国银行签订《保证合同》（合同编号：横 店 2025 年人保字 182 号），同意为公司全资子公司浙江普洛得邦制药有限公司 与中国银行签署的《流动资金借款合同》（合同编号：横店 2025 年人借字 182 号）中的 5,000 万元流动资金贷款提供连带责任保证，担保期限 10 个月。 3、2025 年 11 月 19 日，公司与中 ...

Core Viewpoint - The company, Prolo Pharmaceutical, announced that its drug, Dihydrosulfonic Acid Adenosylmethionine Enteric-Coated Tablets, is expected to be approved in November 2024 and is currently expanding its market presence in the Beijing-Tianjin-Hebei "3+N" alliance and Guangdong alliance [1] Group 1 - The drug is set to receive approval in November 2024 [1] - The company has already won bids in the Beijing-Tianjin-Hebei "3+N" alliance and Guangdong alliance [1] - The company is in the process of rapidly expanding its market [1]

普洛药业股份有限公司 关于第一期员工持股计划存续期即将届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：000739 证券简称：普洛药业 公告编号：2025-72 4、2024 年 3 月 6 日，公司召开第九届董事会第四次会议，审议通过了《关 于公司第一期员工持股计划存续期展期的议案》，同意将公司第一期员工持股计 划存续期展期 24 个月，即存续期展期至 2026 年 5 月 28 日。 具体内容详见公司分别于 2019 年 6 月 12 日、2020 年 6 月 11 日、2022 年 3 月 10 日、2024 年 3 月 8 日刊登在《证券时报》和巨潮资讯网（www.cninfo.com.cn） 上披露的相关公告。 5、截至本公告日，公司第一期员工持股计划通过集中竞价交易方式累计减 持 11,100,000 股；尚持有公司股份 21,564,016 股，占公司目前总股本的 1.86%。 本次员工持股计划持有公司股份均未出现或用于抵押、质押、担保等情形。 普洛药业股份有限公司(以下简称"公司")分别于 2019 年 5 月 10 ...

Core Insights - The establishment of the medical beauty and cosmetics division by Pro Pharmaceutical (普洛药业) on November 4, 2024, aims to enhance quality of life with a focus on product and client development in this sector [2]. Group 1: Business Development - The medical beauty and cosmetics raw materials business is a key development direction for the company, currently in the phase of developing new products and clients [2]. - The company anticipates that the market size for this business segment will experience rapid growth in the coming years [2].

Core Viewpoint - The company has successfully launched its product, Dihydrosilyl Adenosine Methionine Enteric-Coated Tablets, which is recognized for its clear pharmacological mechanism, high safety, and good clinical efficacy, positioning it as a preferred treatment for liver diseases [2]. Company Summary - The product received approval for market launch in November 2024 and is currently expanding its market presence [2]. - The company has secured bids in the Beijing-Tianjin-Hebei "3+N" alliance and the Guangdong alliance, indicating a strategic approach to market penetration [2].

Group 1 - The core focus of the company is on the development of its medical beauty cosmetics raw materials business, which is considered a key growth area [1] - The company is currently in the stage of developing new products and acquiring new customers for this business segment [1] - The market size for this business is expected to achieve rapid growth in the coming years [1]

Group 1 - The core focus of the company is on the development of its medical beauty cosmetics raw materials business, which is considered a key growth area [1] - The company is currently in the stage of developing new products and acquiring new customers for this business segment [1] - The market size for this business is expected to achieve rapid growth in the coming years [1]

Group 1 - Heptagon Pharma announced an update to its global strategic collaboration with AstraZeneca, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) [1] - AstraZeneca will nominate research projects to Heptagon Pharma annually for the next four years, granting them licensing options for these projects [1] - The collaboration reflects the strengthening partnership between Heptagon Pharma and AstraZeneca, highlighting the integration of Chinese biotech companies into the global pharmaceutical ecosystem [1] Group 2 - Prolog Pharma's subsidiary received a drug registration certificate for Cefdinir dry suspension, marking it as the first domestic generic drug approved under the consistency evaluation of quality and efficacy [2] - This approval allows Cefdinir to participate in national medical insurance negotiations, enhancing its market competitiveness [2] Group 3 - Sinovac's recombinant shingles vaccine has received clinical trial approval from the National Medical Products Administration, targeting individuals aged 40 and above [3] - The market for shingles vaccines in China is currently limited, with existing products facing low public willingness for vaccination [3] Group 4 - AstraZeneca announced a $2 billion investment to expand its manufacturing operations in Maryland, marking its fourth major manufacturing investment in the U.S. this year [4] - The company plans to invest $50 billion in the U.S. by 2030 to enhance its manufacturing and R&D capabilities, which is expected to create tens of thousands of jobs [4] Group 5 - Mandi International has submitted its application for listing on the Hong Kong Stock Exchange, focusing on skin health and weight management solutions, with its core brand being a hair loss treatment product [5] - Mandi has ranked first in the Chinese hair loss medication market for ten consecutive years, holding a market share of 57% in 2024 [5] - The company's revenue is highly dependent on a single product, making its IPO progress a point of interest for investors [5]

Core Viewpoint - The company has received a drug registration certificate for Cefdinir Dry Suspension, marking it as the first domestic generic drug approved and deemed to have passed the consistency evaluation of quality and efficacy, which will enhance its market competitiveness and eligibility for national medical insurance negotiations [1][5]. Group 1: Drug Registration Approval - Product Name: Cefdinir Dry Suspension [8] - Dosage Form: Oral Suspension [8] - Specifications: 1.5g (125mg/5ml); 3.0g (250mg/5ml) [8] - Registration Classification: Chemical Drug Class 3 [8] - License Holder: Zhejiang Pro Pharmaceutical Co., Ltd. [8] - Production Company: Zhejiang Pro Pharmaceutical Co., Ltd. [8] - Certificate Numbers: 2025S03414; 2025S03415 [8] - Drug Approval Numbers: National Drug Standard H20255948; H20255949 [8] Group 2: Drug Information - Cefdinir Dry Suspension is a third-generation oral cephalosporin antibiotic, suitable for treating mild to moderate infections in children caused by specified sensitive strains of microorganisms [2]. - Indications include acute bacterial otitis media, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections [2]. Group 3: Market Impact - The estimated market size for Cefdinir oral dosage forms in China's hospital market for 2024 is 530 million tablets, with a sales value of 760 million yuan [3]. - The total R&D investment for Cefdinir Dry Suspension as of the announcement date is 10.2427 million yuan [4]. - The approval of Cefdinir Dry Suspension will facilitate participation in national medical insurance negotiations, thereby expanding market sales and enhancing competitiveness [5].

Group 1: Institutional Research on Popular Companies - The top twenty companies with the highest number of institutional research visits in the last 30 days include United Imaging Healthcare, Lens Technology, Aibo Medical, Sanhua Intelligent Control, and Zhaoyi Innovation [2][13] - In the last 5 days, the most popular companies for institutional research include Ninebot Company-WD, Rongbai Technology, Lens Technology, Yintong Intelligent Control, and Yinglian Co., Ltd [2][15] - Among the top twenty companies in the last 30 days, 19 companies had 10 or more rating agencies involved, with significant profit growth expected for Jiao Cheng Ultrasound, Lanke Technology, and United Imaging Healthcare in Q1-Q3 of 2025 compared to the same period in 2024 [2][13][16] Group 2: Major Shareholder Increase in A-Share Listed Companies - From November 17 to November 21, 2025, five listed companies announced significant shareholder increases, with Changshu Bank increasing its shareholding by more than 1% of total equity, while Huangtai Liquor, Longlide, Fuguang Co., and Feiwo Technology planned to increase their holdings with an average of more than 1% of the market value on the announcement date [3][20] - From January 1 to November 21, 2025, a total of 295 companies announced significant shareholder increases, with 90 of them having 10 or more rating agencies involved. Among these, 23 companies had an average planned increase amount exceeding 1% of the market value on the announcement date, including Xianhe Co., Hubei Yihua, Xinji Energy, and Zhongju Gaoxin [5][22] Group 3: Share Buyback Situation in A-Share Listed Companies - From November 17 to November 21, 2025, 65 companies announced their buyback progress, with 16 companies having 10 or more rating agencies involved. Five companies had an average planned buyback amount exceeding 1% of the market value on the announcement date, with a focus on Jian Sheng Group, Trina Solar, and Prologis Pharmaceuticals [4][25] - From January 1 to November 21, 2025, a total of 1,805 companies announced their buyback progress, with 344 of them having 10 or more rating agencies involved. Among these, 88 companies had a significant buyback ratio, with two companies, Huaming Equipment and Prologis Pharmaceuticals, still in the board proposal stage [6][27]